Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants

Mukai, Y; Narita, M; Akiyama, E; Ohashi, K; Horiuchi, Y; Kato, Y; Toda, T; Rane, A; Inotsume, N

Toda, T (reprint author), Hokkaido Pharmaceut Univ, Div Clin Pharmacol, Sch Pharm, 7 Jo 15 Chome,4-1 Maeda, Sapporo, Hokkaido 0068590, Japan.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017; 40 (7): 1078

Abstract

Fluvastatin, which is one of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins), is primarily metabolized by CYP2C9 and to a lesse......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索